Belite Bio, Inc.(BLTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BLTE Belite Bio, Inc.

Market Closed 11-13 16:00:00 EST

164.36

-5.60

-3.30%

盘后164.36

+0.000.00%

19:30 EST

High170.75	Low156.43	Vol216.98K
Open170.75	D1 Closing169.96	Amplitude8.43%
Mkt Cap6.62B	Tradable Cap3.21B	Total Shares40.27M
T/O35.40M	T/O Rate1.11%	Tradable Shares19.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BLTE","market":"US","secType":"STK","nameCN":"Belite Bio, Inc.","latestPrice":164.355,"timestamp":1794603600000,"preClose":169.96,"halted":0,"volume":216976,"hourTrading":{"tag":"盘后","latestPrice":164.355,"preClose":164.355,"latestTime":"19:30 EST","volume":951,"amount":156301.605,"timestamp":1794616201612,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.032978347846552236,"floatShares":19550700,"shares":40272144,"eps":-2.738223,"marketStatus":"Market Closed","change":-5.605,"latestTime":"11-13 16:00:00 EST","open":170.75,"high":170.75,"low":156.43,"amount":35398093.8704,"amplitude":0.084255,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.738223,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794819600000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1651204800000,"exchange":"NASDAQ","adjPreClose":169.96,"preHourTrading":{"tag":"盘前","latestPrice":171.5,"preClose":169.96,"latestTime":"09:25 EST","volume":942,"amount":162998.6874,"timestamp":1794579937545,"change":1.54,"changeRate":0.009061,"amplitude":0.024888},"postHourTrading":{"tag":"盘后","latestPrice":164.355,"preClose":164.355,"latestTime":"19:30 EST","volume":951,"amount":156301.605,"timestamp":1794616201612,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7961037238136458,"impliedVol":0.6382,"impliedVolPercentile":0.0588},"requestUrl":"/m/hq/s/BLTE/wiki","defaultTab":"wiki","newsList":[{"id":"2683688488","title":"Belite Bio is Maintained at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2683688488","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683688488?lang=en_us&edition=fundamental","pubTime":"2026-11-14 04:33","pubTimestamp":1794601980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BLTE/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683425501","title":"Mizuho Adjusts Price Target on Belite Bio to $230 From $221, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2683425501","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683425501?lang=en_us&edition=fundamental","pubTime":"2026-11-13 23:21","pubTimestamp":1794583298,"startTime":"0","endTime":"0","summary":"Belite Bio (BLTE) has an average rating of buy and mean price target of $232, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683059605","title":"Belite Bio, Inc : Canaccord Genuity Raises Target Price to $314 from $303","url":"https://stock-news.laohu8.com/highlight/detail?id=2683059605","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683059605?lang=en_us&edition=fundamental","pubTime":"2026-11-13 21:35","pubTimestamp":1794576940,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261113:nFWN46U1W1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683571596","title":"Belite Bio, Inc : Leerink Partners Raises Target Price to $215 from $185","url":"https://stock-news.laohu8.com/highlight/detail?id=2683571596","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683571596?lang=en_us&edition=fundamental","pubTime":"2026-11-13 18:18","pubTimestamp":1794565109,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261113:nFWN46U0Q7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683227415","title":"US Research Roundup-Azenta, Cencora, Stratasys","url":"https://stock-news.laohu8.com/highlight/detail?id=2683227415","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683227415?lang=en_us&edition=fundamental","pubTime":"2026-11-13 15:25","pubTimestamp":1794554746,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-Azenta, Cencora, StratasysNov 13 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Azenta, Cencora and Str","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261113:nL3N46U0QV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMH","COR","FLUT","PANW","ANF","EXEL","AMG","FPS","KSS","CLF","AEO","NPCE","XNTK","BUG","NIQ","AVR","NTSK","HTFL","DORM","BMRN","NBIX","IHF","LGN","CARS","SPAM","DNLI","DECK","KARD","TDV","HCA","RS","CTVA","LOW","PANG","AXSM","BBIO","JAZZ","BLTE","CGON","WCBR","BBWI","ACAD","AZTA","AMAT","SBIO","PSWD","ANDG","BRUN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682971205","title":"Belite Bio, Inc Reports Results for the Quarter Ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2682971205","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682971205?lang=en_us&edition=fundamental","pubTime":"2026-11-12 22:31","pubTimestamp":1794493874,"startTime":"0","endTime":"0","summary":"Belite Bio, Inc reports results for the quarter ended September 30 - Earnings SummaryBelite Bio, IncBLTE.OQreported a quarterly adjusted loss of 65 cents per share for the quarter ended September 30, ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nL5N46T1UV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682780560","title":"Belite Bio Q3 Net Loss Widens 40% to $30.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2682780560","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682780560?lang=en_us&edition=fundamental","pubTime":"2026-11-12 19:51","pubTimestamp":1794484305,"startTime":"0","endTime":"0","summary":"Belite Bio Q3 Net Loss Widens 40% to $30.3 MillionBelite Bio’s third-quarter 2026 net loss widened 40% year over year to $30.3 million.Selling, general and administrative expenses rose 69% year over y","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nNDL55BJQW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682567665","title":"Belite Bio's Q3 Adjusted Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2682567665","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682567665?lang=en_us&edition=fundamental","pubTime":"2026-11-12 19:20","pubTimestamp":1794482401,"startTime":"0","endTime":"0","summary":"Belite Bio (BLTE) reported a Q3 adjusted loss Thursday of $0.60 per diluted share, compared with an adjusted loss of $0.26 a year earlier.An analyst polled by FactSet expected a loss of $0.52.As of Sept. 30, the company had cash and cash equivalents of $271.3 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682673735","title":"Belite Bio Q3 Net Income USD -30.273 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2682673735","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682673735?lang=en_us&edition=fundamental","pubTime":"2026-11-12 19:17","pubTimestamp":1794482263,"startTime":"0","endTime":"0","summary":"Nov 12 (Reuters) - Belite Bio Q3 income from operations USD -36.91 million.:((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 12-NOV-202611:01:03.633 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nRSD2p2pmP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682562408","title":"Belite Bio Q3 Loss Widens on Higher Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2682562408","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682562408?lang=en_us&edition=fundamental","pubTime":"2026-11-12 19:08","pubTimestamp":1794481684,"startTime":"0","endTime":"0","summary":"Belite Bio Q3 loss widens on highercostsOverviewUS retinal drug developer's Q3 net loss widened yr/yr on higher R&D and SG&A costsCompany's lead drug tinlarebant granted FDA priority review for Starga","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nL2N46T0IW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IONS","OCUL","BLTE","BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682980562","title":"Belite Bio Q3 EPS $(0.65) Beats $(0.80) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2682980562","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682980562?lang=en_us&edition=fundamental","pubTime":"2026-11-12 19:01","pubTimestamp":1794481307,"startTime":"0","endTime":"0","summary":"Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.80) by 18.75 percent. This is unchanged from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/11/63174865/belite-bio-q3-eps-0-65-beats-0-80-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTEC","QID",".IXIC","03086","IYW","QDTE","TECS","BK4007","QQQJ","JEPQ","TQQY","QQQA","ONEQ","QLD","NDX","NQmain","QYLG","QQQE","MNQmain","GPIQ","PSQ","QQQM","QQQ","BLTE","SQQQ","QQQY","TQQQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682456232","title":"Belite Bio Q3 Pretax Profit USD -30.26 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2682456232","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682456232?lang=en_us&edition=fundamental","pubTime":"2026-11-12 19:00","pubTimestamp":1794481203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nPLXZVC4SF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682562627","title":"Press Release: Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2682562627","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682562627?lang=en_us&edition=fundamental","pubTime":"2026-11-12 19:00","pubTimestamp":1794481200,"startTime":"0","endTime":"0","summary":"-- New Drug Application  for tinlarebant in Stargardt disease type 1.  granted priority review by the U.S. Food and Drug Administration.  in August 2026 with Prescription Drug User Fee Act  target. -- Company has been informed by the FDA that it will not convene an advisory. -- Submitted NDA for tinlarebant to Japan's Ministry of Health, Labour and. -- Submitted Marketing Authorization Applications for tinlarebant in. Singapore, the United Kingdom, and Switzerland via the Access Consortium. -- Company uplisted to the Nasdaq Global Select Market. -- Conference call and webcast on Thursday, November 12, 2026, at 4:30 p.m.global, multi-center, pivotal Phase 3 trial in adolescent STGD1 patients.-- In August 2026, the FDA accepted the NDA for tinlarebant in STGD1. and granted Priority Review, with an assigned PDUFA target action. -- The Company has been informed by the FDA that it will not convene. an advisory committee meeting to discuss the NDA for tinlarebant. in STGD1. The FDA's review ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BLTE","BK4585","LABU","BK4022","BK4007","R","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682832715","title":"Is Belite Bio (BLTE) Undervalued After Tinlarebant Won FDA Priority Review?","url":"https://stock-news.laohu8.com/highlight/detail?id=2682832715","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682832715?lang=en_us&edition=fundamental","pubTime":"2026-11-11 23:22","pubTimestamp":1794410557,"startTime":"0","endTime":"0","summary":"SSasha JovanovicNovember 11, 2026","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-blte/belite-bio/news/is-belite-bio-blte-undervalued-after-tinlarebant-won-fda-pri","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-blte/belite-bio/news/is-belite-bio-blte-undervalued-after-tinlarebant-won-fda-pri","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4007","LABU","BK4588","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682316279","title":"Is Priority FDA Review Altering The Investment Case For Belite Bio (BLTE)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2682316279","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682316279?lang=en_us&edition=fundamental","pubTime":"2026-11-10 22:23","pubTimestamp":1794320598,"startTime":"0","endTime":"0","summary":"BBailey PembertonNovember 10, 2026","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-blte/belite-bio/news/is-priority-fda-review-altering-the-investment-case-for-beli","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-blte/belite-bio/news/is-priority-fda-review-altering-the-investment-case-for-beli","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BLTE","BK4585","BK4007","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682156593","title":"Belite Bio, Inc Expected to Post a Loss of 77 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2682156593","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682156593?lang=en_us&edition=fundamental","pubTime":"2026-11-10 22:08","pubTimestamp":1794319687,"startTime":"0","endTime":"0","summary":"Belite Bio, Inc <BLTE.OQ> expected to post a loss of77cents a share - Earnings PreviewBelite Bio, IncBLTE.OQBLTE.Ois expected to  show no change in quarterly revenue when it reports  results on Novemb","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261110:nL5N46R1KX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681073480","title":"Belite Bio to Host Third-Quarter Financial Results Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2681073480","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681073480?lang=en_us&edition=fundamental","pubTime":"2026-11-05 21:09","pubTimestamp":1793884192,"startTime":"0","endTime":"0","summary":"Belite Bio to Host Third-Quarter Financial Results WebcastBelite Bio will host a webcast November 12, 2026, to discuss third-quarter 2026 financial results.Scheduled for 4:30 p.m. Eastern Time (1:30 p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nNDL3ry6HR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2210149790.SGD","IE00B3QW5Z07.USD","BK4112","SG9999014005.SGD","SG9999014021.USD","BK4585","NDAQ","IE00B64PRP62.GBP","BK4007","LU2210150020.SGD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014013.SGD","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","SG9999014039.USD","BLTE","BK4588","LU2095319765.USD","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679242250","title":"US Research Roundup-Baker Hughes, Brinker International, GE Vernova","url":"https://stock-news.laohu8.com/highlight/detail?id=2679242250","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679242250?lang=en_us&edition=fundamental","pubTime":"2026-10-29 15:25","pubTimestamp":1793258720,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-Baker Hughes, Brinker International, GE VernovaOct 29 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Ba","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261029:nL3N46F0MU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GOOG","BA","BCAX","BXP","BSX","PEX","ARCC","ALGN","AVBH","BOEG","GLAM","ALKT","FCOM","CNC","BOOT","BKR","BRO","AXSM","RSPU","BLKB","CSTL","CPF","ADP","AVTR","CCS","CNP","GOOGL","AMLX","BBWI","AXGN","CVNA","SKYY","SNPE","ALK","ANT","APH","BIIB","ETSY","GOOP","EAT","ARHS","AUR","CBC","BANC","BLTE","BOED","CHRW","BNTC","AEP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677963494","title":"Two new option listings and one option delisting on October 22nd","url":"https://stock-news.laohu8.com/highlight/detail?id=2677963494","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677963494?lang=en_us&edition=fundamental","pubTime":"2026-10-22 20:36","pubTimestamp":1792672566,"startTime":"0","endTime":"0","summary":"New option listings for October 22nd include Belite Bio Inc (ADR) (BLTE) and Getty Images Holdings, Inc. (GETYQ). Option delistings effective Octob...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/two-new-option-listings-and-one-option-delisting-on-october-22nd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/two-new-option-listings-and-one-option-delisting-on-october-22nd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CVY","SAPH","ARMH","APIE","DIVL","DINT","BLTE","AADR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124625844","title":"Morgan Stanley Initiates Eight Biotech Names, Rating Seven Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=1124625844","media":"Analyst Calls","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124625844?lang=en_us&edition=fundamental","pubTime":"2026-10-20 10:11","pubTimestamp":1792462284,"startTime":"0","endTime":"0","summary":"","market":"us","thumbnail":"https://static.tigerbbs.com/96e20408c3934de428b82e38a778cc26","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/96e20408c3934de428b82e38a778cc26"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Morgan Stanley Initiates Eight Biotech Names, Rating Seven Overweight","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","BLTE","RGNX","PTCT","AVLN","TRVI"],"isVideo":true,"video":{"duration":320,"video_url":"https://news-video-sg.skytigris.cn/videos/remotion/3928/render_3928_1792461663591.mp4","video_thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/3928.webp","audio_url":"https://news-video-sg.skytigris.cn/videos/remotion/3928/tts/voiceover_2510d0822d39909bff1e8933.mp3","isAI":true},"gpt_icon":0}],"profile":{"websiteUrl":"http://investors.belitebio.com;belitebio.com","stockEarnings":[{"period":"1week","weight":0.0659},{"period":"1month","weight":0.0762},{"period":"3month","weight":0.0096},{"period":"6month","weight":0.1493},{"period":"1year","weight":0.4621},{"period":"ytd","weight":0.0275}],"compareEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":-0.0198},{"period":"3month","weight":-0.0283},{"period":"6month","weight":0.0206},{"period":"1year","weight":0.1225},{"period":"ytd","weight":0.1062}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.020711},{"month":2,"riseRate":0.75,"avgChangeRate":0.070972},{"month":3,"riseRate":0.25,"avgChangeRate":-0.067883},{"month":4,"riseRate":0.25,"avgChangeRate":-0.011914},{"month":5,"riseRate":0.6,"avgChangeRate":0.032881},{"month":6,"riseRate":0.4,"avgChangeRate":0.163367},{"month":7,"riseRate":1,"avgChangeRate":0.188852},{"month":8,"riseRate":0.2,"avgChangeRate":0.073935},{"month":9,"riseRate":0.6,"avgChangeRate":0.03995},{"month":10,"riseRate":0.6,"avgChangeRate":0.161477},{"month":11,"riseRate":0.8,"avgChangeRate":0.111691},{"month":12,"riseRate":0.5,"avgChangeRate":0.042173}],"exchange":"NASDAQ","name":"Belite Bio, Inc.","nameEN":"Belite Bio, Inc.","securityTypeName":"DR","adrRate":"1:1"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Belite Bio, Inc.(BLTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Belite Bio, Inc.(BLTE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Belite Bio, Inc.,BLTE,Belite Bio, Inc.股票,Belite Bio, Inc.股票老虎,Belite Bio, Inc.股票老虎国际,Belite Bio, Inc.行情,Belite Bio, Inc.股票行情,Belite Bio, Inc.股价,Belite Bio, Inc.股市,Belite Bio, Inc.股票价格,Belite Bio, Inc.股票交易,Belite Bio, Inc.股票购买,Belite Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Belite Bio, Inc.(BLTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Belite Bio, Inc.(BLTE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}